The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically altered by the development of metastatic recurrence. However, there are very few indicators that can predict which patient will develop a recurrence. MicroRNAs regulate many cellular processes and have been shown to be associated with cancer development and recurrence. More recently it has been shown that microRNA genes can be epigenetically modified in cancer, resulting in aberrant silencing of microRNA genes with tumor suppressor functions. In this study, we show that two genes encoding for hsa-miR-9 are significantly hypermethylated in ccRCC tumors compared with adjacent normal tissues (P-value o0.001 for both miR-9-1 and miR-9-3) resulting in decreased expression, and that the methylation of these genes was more significant in DNA obtained from the primary tumor for patients who developed a recurrence (P-value: 0.012 and 0.009 for miR-9-1 and miR-9-3, respectively) than in tumors from nonrecurrent patients. Furthermore, methylation of miR-9-3 was significantly associated with an increased risk of recurrence (hazard ratio: 5.85, 95% confidence intervals: 1.30-26.35) and high methylation levels of either miR-9-1 or miR-9-3 resulted in a significant, nearly 30-month decrease in recurrence-free survival time (P-value: 0.034 and 0.007 for miR-9-1 and miR-9-3, respectively). Our results demonstrate that hsamiR-9 is involved in the development of ccRCC while also having a role in the development of metastatic recurrence.
Introduction
Renal cell carcinoma (RCC) is the seventh most common cancer in the United States and is predicted to result in nearly 13 000 deaths in 2009 (Jemal et al., 2009) . Surgery is the first line of treatment with successful resection, often resulting in long-term disease-free status. Although the overall survival rate is more than 60% over 5 years (Jemal et al., 2009) , B30% of patients who are diagnosed with localized RCC develop a metastatic recurrence (Pantuck et al., 2001) . These patients have a very poor prognosis because of the refractory nature of RCC to current treatment regimens. Therefore, there has been much interest in the identification of biomarkers for RCC to better predict cancer development and prognosis.
MicroRNAs are small, non-coding RNAs that have been found to regulate expression through targeted repression of gene transcription and translation. Gene expression of microRNAs can modulate several important cellular functions and have been shown to be involved in the development of cancer (Garzon et al., 2009) . Recently, it has been shown that microRNA genes can also be epigenetically modified (Lujambio and Esteller, 2007) . One of these methylated microRNAs is hsa-miR-9. The mature hsa-miR-9 transcript is produced by three independent genes: miR-9-1, miR-9-2 and miR-9-3, located on chromosomes 1, 5 and 15, respectively. Previous studies have shown that these microRNA genes are commonly hypermethylated in tumor tissue (Lehmann et al., 2008; Lujambio et al., 2008; Omura et al., 2008; Bandres et al., 2009; Hsu et al., 2009) . Furthermore, hsa-miR-9 methylation was shown to be associated with the development of metastasis (Lujambio et al., 2008; Bandres et al., 2009) . However, this phenomenon has not been reported for clear cell renal cell carcinoma (ccRCC).
In this study, we determined the methylation status of miR-9-1 and miR-9-3 in ccRCC tumor tissue compared with adjacent normal. We then determined whether methylation of these microRNA genes in the primary tumor was associated with the development of metastatic recurrence in these patients. This is the first evidence that implicates epigenetic modifications of hsamiR-9 genes as potential mechanisms for ccRCC development and risk of metastatic recurrence.
Results

Patient characteristics
The characteristics of the patient population are in agreement with known risk factors for ccRCC (Table 1 ).
The mean age at diagnosis was 59 years and a majority of the patients were males and Caucasian. The mean body mass index was over 30 indicating that these individuals were overweight or obese. Over half had a family history of cancer and a history of hypertension.
Epigenetic silencing of hsa-miR-9 in ccRCC The mature hsa-miR-9 transcript is produced by three independent genes: miR-9-1, miR-9-2 and miR-9-3, located on chromosomes 1, 5 and 15, respectively. Large CpG islands over 1000 basepairs in length are located upstream of miR-9-1 and surrounding miR-9-3 ( Figure 1a ). We performed methylation-specific realtime PCR experiments on DNA extracted from 32 ccRCC tumor and adjacent normal pairs. There was a significant increase in methylation for both miR-9-1 and miR-9-3 in tumor tissues compared with adjacent normal tissues (P-value: 0.00021 and 0.000074, respectively; Figure 1b) . Methylation of miR-9-1 was increased nearly twofold, whereas miR-9-3 increased over fourfold. Furthermore, there was a significant trend toward increased methylation in tumor samples of higher clinical stages for both miR-9-1 (P-value: 0.024) and miR-9-3 (P-value: 0.040).
Epigenetic silencing of hsa-miR-9 in ccRCC recurrence This hypermethylation of miR-9-1 and miR-9-3 has reported to be even more frequent in metastatic disease. Therefore, we next analyzed the methylation status of the hsa-miR-9 genes in cases that have had a metastatic recurrence and in cases that have not developed a metastatic recurrence in our population. Of the 74 tumors profiled, 59 had follow-up information regarding recurrence. Indeed, in comparisons of DNA from the 21 tumors that developed a metastatic recurrence and DNA from the 38 tumors with no recurrence development at follow-up, we observed that patients who developed a recurrence had a significant increase in hypermethylated miR-9-1 and miR-9-3 in their primary tumor (P-value: 0.012 and 0.0092, respectively). Furthermore, when patients were split into two groups based on the median methylation level of miR-9-1 and miR-9-3, an increase in recurrence risk was observed (hazard ratio: 2.74, 95% confidence intervals: 0.78-9.60 and hazard ratio: 5.85, 95% confidence intervals: 1.30-26.35, respectively). Although this increase in risk was not statistically significant for miR-9-1, both of these increases in risk corresponded to significant >30-month reductions in recurrence-free survival times for patients with high miR-9-1 and miR-9-3 methylation levels (P-value: 0.034 and 0.007, respectively; Figures 2a and b).
Discussion
Prognosis for ccRCC patients is dramatically worse following the development of metastatic recurrence resulting in a strong need for biomarkers that can help to predict which patients are at an increase risk of recurrence. In this study, we first analyzed ccRCC tumor and adjacent normal tissue samples for differences in miR-9-1 and miR-9-3 methylation status and identified significant hypermethylation of both genes in tumor samples. These two genes were also highly methylated in primary tumors of patients who developed metastatic recurrences and were associated with increased risk for recurrence. These results suggest that hsa-miR-9 functions as a tumor suppressor for ccRCC tumorigenesis, and methylation status of miR-9-1 and/or miR-9-3 could be a biomarker for a poor prognosis due to the development of metastatic recurrence.
Previous studies have shown extensive epigenetic silencing of one or several of the miR-9 genes in cancer (Lehmann et al., 2008; Lujambio et al., 2008; Omura et al., 2008; Bandres et al., 2009; Hsu et al., 2009) . This silencing was common in tumor tissue, whereas nearly absent in normal tissue. For example, in pancreatic adenocarcinoma, miR-9-1 was found to be methylated Hsa-miR-9 methylation and renal cell carcinoma MAT Hildebrandt et al in 89% of the tumor samples, but only 15% of the normal tissues (Omura et al., 2008) . Furthermore, methylation of lysine residues 9 and 27 of histone H3, hallmarks of epigenetic gene silencing, was associated with miR-9-3 when gene expression was suppressed in breast cancer (Hsu et al., 2009) . We observed similar patterns of miR-9-1 and miR-9-3 methylation in comparisons between ccRCC tumors and adjacent normal tissue. Our results could potentially be even stronger if we had utilized laser dissected tissue specimens and nonadjacent normal samples. These approaches would have decreased the possibility of normal/tumor cross-contamination. However, the differences between the methylation statuses of miR-9-1 and miR-9-3 are clearly evident utilizing these specimens. Hypermethylation of the two hsa-miR-9 genes has been shown to be even more evident in tumors with lymph node metastases in colon, lung, breast and melanoma cancers (Lujambio et al., 2008; Bandres et al., 2009 ). In our ccRCC tumor samples, this was also observed with patients developing a recurrence having a higher occurrence of methylated miR-9-1 and miR-9-3 in their primary tumor compared with those who have not at time of analysis (Figure 2) . Furthermore, this increase in methylation was associated with a significant increase in recurrence risk and decreased recurrence-free survival durations. These analyzes were performed while adjusting for several known ccRCC risk factors, such as history of hypertension, body mass index, smoking behavior and gender, minimizing the probability that the observed association is because of confounding factors. These results indicate the methylation of hsa-miR-9 genes is an important factor influencing recurrence risk for ccRCC patients.
In addition to analysis of hsa-miR-9 methylation status, microRNA expression studies have shown that hsa-miR-9 expression is downregulated for several cancer sites, including breast (Lehmann et al., 2008; Hsu et al., 2009) Hsa-miR-9 methylation and renal cell carcinoma MAT Hildebrandt et al gastric (Luo et al., 2009 ) and ovarian (Laios et al., 2008) . Furthermore, studies of liver (Budhu et al., 2008) , breast (Iorio et al., 2005) and colorectal (Bandres et al., 2009) cancers have shown that altered hsa-miR-9 expression was associated with metastatic tumors. Our findings are that both miR-9-1 and miR-9-3 are hypermethylated, and thus silenced in tumor compared with adjacent normal, and also in the primary tumors of those who developed recurrences compared with those who did not are in agreement with the published expression data. According to the TargetScan database (www. targetscan.org; Lewis et al., 2005) , there are over 900 predicted hsa-miR-9 targets, including several well known cancer genes. These genes are involved with important cellular pathways such as regulation of transcription and cell differentiation. In addition, previous microarray studies have demonstrated that forced hsa-miR-9 expression in breast cancer cell lines with normally epigenetically silenced miR-9-3 resulted in significant expression changes for multiple genes in the p53 signaling pathway (Hsu et al., 2009) . This expression of hsa-miR-9 also caused an increase in apoptotic activity in those cells. These results give further support that hsa-miR-9 has an important role in the development of cancer and particularly metastatic disease through regulation of multiple cancer-related genes. Future studies identifying the hsamiR-9 target genes specific for the development of metastatic recurrence in ccRCC would be of great interest.
In conclusion, we identified hsa-miR-9 as a tumor suppressor in ccRCC and also its association within the development of metastatic recurrence. These results strongly implicate hsa-miR-9 as a candidate for ccRCC prognosis and provide a potential biomarker for recurrence risk prediction. Together with other known risk factors, these results may be used to identify ccRCC patients who require much more intensive treatment to prevent the occurrence of recurrence and enhance overall survival.
Materials and methods
Patient population
Tumor tissue was obtained from 74 newly diagnosed, histologically confirmed ccRCC patients recruited from The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Adjacent normal tissue was also available for 32 of these cases. Cases were identified through a daily review of computerized appointment schedules for the Department of Urology and Genitourinary Medical Oncology with no restrictions on age, gender, ethnicity or stage at recruitment. Information regarding demographics, occupational history, tobacco and alcohol use history, medical history and family history of cancer were collected using risk factor questionnaires. Clinical information on clinical stage, history of hypertension and body mass index was abstracted from medical records. Informed consent was obtained from all patients and the study was approved by MD Anderson Cancer Center's Institutional Review Board.
